- Trials with a EudraCT protocol (322)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (2)
322 result(s) found for: Enzyme activity.
Displaying page 1 of 17.
EudraCT Number: 2006-002192-40 | Sponsor Protocol Number: periodld001 | Start Date*: 2006-07-13 |
Sponsor Name:Zsolt Lohinai DMD PhD | ||
Full Title: New treatment of periodontitis by inhibition of lysine decarboxilase enzyme | ||
Medical condition: healthy volunteers | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: HU (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2011-002750-31 | Sponsor Protocol Number: LAL-CL02 | Start Date*: 2013-05-29 | |||||||||||
Sponsor Name:Alexion Pharmaceuticals, Inc. | |||||||||||||
Full Title: A multicenter, randomized, placebo-controlled study of SBC-102 in patients with lysosomal acid lipase deficiency | |||||||||||||
Medical condition: Lysosomal Acid Lipase Deficiency | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) IT (Completed) ES (Completed) CZ (Completed) PL (Completed) GR (Completed) HR (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-004370-34 | Sponsor Protocol Number: POM-003 | Start Date*: 2018-04-09 | |||||||||||
Sponsor Name:Amicus Therapeutics, Inc. | |||||||||||||
Full Title: A Prospective Study in Subjects with Late-onset Pompe Disease who are Currently Being Treated with Enzyme Replacement Therapy | |||||||||||||
Medical condition: Late-onset Pompe disease (LOPD) in subjects receiving standard-of-care enzyme replacement therapy (ERT) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Prematurely Ended) HU (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-001629-27 | Sponsor Protocol Number: AGLU02403 | Start Date*: 2005-08-03 |
Sponsor Name:Genzyme Europe BV | ||
Full Title: A Long-term Continuation Study of Patients with Infantile-Onset Pompe Disease who were previously enrolled in Protocol AGLU01602 | ||
Medical condition: Pompe disease is a rare metabolic muscle disease inherited in an autosomal recessive fashion. Pompe disease is caused by a deficiency of GAA, which is needed for the degradation of lysosomal glyco... | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | |
Trial protocol: DE (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2016-001638-84 | Sponsor Protocol Number: 16-07 | Start Date*: 2016-07-08 |
Sponsor Name:Meander Medical Center | ||
Full Title: Thiopurines with Low Dose Allopurinol: a prospective one way cross-over study | ||
Medical condition: Crohn's disease & Colitis Ulcerosa | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-001513-13 | Sponsor Protocol Number: LAL-CL04 | Start Date*: 2011-10-24 | |||||||||||||||||||||
Sponsor Name:Synageva Biopharma Corp. | |||||||||||||||||||||||
Full Title: AN OPEN LABEL MULTICENTER EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF SBC-102 IN ADULT SUBJECTS WITH LIVER DYSFUNCTION DUE TO LYSOSOMAL ACID LIPASE DEFICIENCY WH... | |||||||||||||||||||||||
Medical condition: Lysosomal Acid Lipase (LAL) Deficiency is a rare autosomal recessive lipid storage disorder that is caused by deficient activity or absence, of the lysosomal enzyme, LAL. It is an extremely rare di... | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: GB (Completed) CZ (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2010-018531-17 | Sponsor Protocol Number: TRED012010 | Start Date*: 2010-06-25 |
Sponsor Name:Central Manchester University Hospitals NHS Foundation Trust | ||
Full Title: Effect of Tredaptive on serum lipoproteins, lipoproteins metabolism, oxidative stress and HDL antioxidant function. | ||
Medical condition: Hypercholesterolaemia. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-002674-36 | Sponsor Protocol Number: 49929 | Start Date*: 2017-10-12 |
Sponsor Name: | ||
Full Title: DOES ARGININE ENHANCE GALACTOSE OXIDATIVE CAPACITY IN CLASSIC GALACTOSEMIA? A PILOT STUDY | ||
Medical condition: Classic galactosemia | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2014-000533-22 | Sponsor Protocol Number: LAL-CL08 | Start Date*: 2014-05-28 | |||||||||||
Sponsor Name:Alexion Pharmaceuticals Inc | |||||||||||||
Full Title: A Phase 2, Open Label, Multicenter Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Sebelipase Alfa in Infants with Rapidly Progressive Lysosomal Acid Lipase Deficiency | |||||||||||||
Medical condition: Lysosomal Acid Lipase Deficiency (LALD) | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) IT (Completed) FI (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-000032-28 | Sponsor Protocol Number: LAL-CL03 | Start Date*: 2011-04-18 | |||||||||||||||||||||
Sponsor Name:Synageva Biopharma Corp. | |||||||||||||||||||||||
Full Title: An Open Label, Multicenter, Dose Escalation Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of SBC-102 in Children with Growth Failure Due to Lysosomal ... | |||||||||||||||||||||||
Medical condition: Growth failure in children due to lysosomal acid lipase deficiency (Wolman disease). | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: GB (Completed) FR (Completed) DE (Prematurely Ended) IT (Completed) IE (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2008-006451-52 | Sponsor Protocol Number: 4474 | Start Date*: 2009-01-27 | |||||||||||
Sponsor Name:Newcastle upon Tyne Hospitals NHS Foundation Trust | |||||||||||||
Full Title: An investigation of the association between vitamin K intake, vitamin K epoxide reductase subunit (VKORC1) genotype and anticoagulation response to warfarin | |||||||||||||
Medical condition: Patients will be recruited who are receiving long term warfarin therapy for the treatment or prevention of venous or arterial thrombosis or embolism | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-001375-11 | Sponsor Protocol Number: not applicable | Start Date*: 2007-05-16 |
Sponsor Name: | ||
Full Title: Effects and health economic aspects of enzyme therapy in children and adults with Pompe disease Long-term follow-up of patients receiving commercially available Myozyme | ||
Medical condition: Pompe disease (glycogen storage disease type II) is a genetic, lysosomal storage disorder with a frequency of 1 in 40.000 newborns. The disease is caused by deficiency of alpha-glucosidase, a lysos... | ||
Disease: | ||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2013-001974-11 | Sponsor Protocol Number: HEPATOTEST | Start Date*: 2013-08-29 |
Sponsor Name:INSTITUTO DE INVESTIGACION SANITARIA LA FE | ||
Full Title: PILOT TRIAL FOR THE EVALUATION OF HEPATOTEST IN PREOPERATIVE ASSESSMENT IN LIVER FUNCTION. | ||
Medical condition: Patients with liver metastases (mainly colorectal cancer) who will be undergoing major hepatic resection (3 or more liver segments) which have been treated with neoadjuvant chemotherapy. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2010-024647-32 | Sponsor Protocol Number: MIGLU-3 | Start Date*: 2011-03-18 | |||||||||||
Sponsor Name:UNIVERSITA` DEGLI STUDI DI NAPOLI FEDERICO II | |||||||||||||
Full Title: Combined enzyme enhancement therapy (EET) and enzyme replacement therapy (ERT) in patients with Pompe disease | |||||||||||||
Medical condition: Patients with Pompe Disease (Type II Glycogenosis) on therapy with Enzyme Replacement Therapy (ERT) for at least 6 months | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-024068-16 | Sponsor Protocol Number: LAL-CL01 | Start Date*: 2011-03-08 | |||||||||||||||||||||
Sponsor Name:Synageva Biopharma Corp. | |||||||||||||||||||||||
Full Title: An open label multicenter study to evaluate the safety, tolerability and pharmacokinetics of SBC-102 in adult patients with liver dysfunction due to lysosomal acid lipase deficiency. | |||||||||||||||||||||||
Medical condition: Lysosomal Acid Lipase (LAL) Deficiency is a rare autosomal recessive lipid storage disorder that is caused by deficient activity or absence, of the lysosomal enzyme, LAL. It is an extremely rare di... | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: GB (Completed) CZ (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-000645-48 | Sponsor Protocol Number: AGU-001 | Start Date*: 2017-09-21 |
Sponsor Name:Minna Laine [...] | ||
Full Title: Open-label study to evaluate efficacy and safety of Cystadane for the treatment of aspartylglucosaminuria | ||
Medical condition: Aspartylglucosaminuria | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: FI (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2005-005295-32 | Sponsor Protocol Number: TRALIS001 | Start Date*: 2006-02-01 |
Sponsor Name:Research and Development Department, Addenbrookes NHS Foundation Trust | ||
Full Title: Trial in rheumatoid arthritis of lisinopril (TRALIS) | ||
Medical condition: Rheumatoid arthritis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-000788-26 | Sponsor Protocol Number: 3/085/11 | Start Date*: 2012-06-18 |
Sponsor Name: [...] | ||
Full Title: The Effects of Inorganic Nitrite on cardiac and skeletal muscle: Physiology, Pharmacology and Therapeutic Potential in patients with Chronic Heart Failure | ||
Medical condition: Chronic heart failure | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2005-004684-31 | Sponsor Protocol Number: 2809SELENIUM | Start Date*: 2006-04-20 |
Sponsor Name:Barts and the London NHS Trust | ||
Full Title: Does Selenium Supplementation reduce Oxidative Stress associated with Subarachnoid Haemorrhage? | ||
Medical condition: Patients with spontaneous subarachnoid haemorrhage (non-traumatic) admitted to the Intensive Vare Unit of the Royal London Hospital. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-001438-34 | Sponsor Protocol Number: 20-101 | Start Date*: 2005-05-23 |
Sponsor Name:McNeil Consumer and Specialty Pharmaceuticals | ||
Full Title: A Phase II, Randomized, Investigator-Blinded, Parallel-Group, Pilot Study Evaluating the Safety, Palatability and Efficacy of Four Doses of Pancrelipase Microtablets in the Treatment of Infants and... | ||
Medical condition: Cystic Fibrosis-Related Pancreatic Insufficiency and Fat Malabsorption | ||
Disease: | ||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
